特比澳对肝病合并血小板减少症患者的疗效分析

Analysis of application of Recombinant Human Thrombopoietin in patients with liver disease complicated with thrombocytopenia

目的分析特比澳对肝病合并血小板减少症患者的疗效。方法选取南京市第二医院在2020年3月至2021年3月收治的肝病合并血小板减少症患者120例,分为对照组、研究组各60例。对照组使用地塞米松治疗,研究组使用特比澳治疗。对比两组肝功能指标、凝血功能、血常规、炎症相关指标、免疫相关指标及血小板计数(PLT)水平,并分析有效性、安全性。结果治疗后研究组ALT、AST、TBil分别为(28.89±6.55)U/L、(33.14±5.56)U/L、(16.98±3.63)μmol/L,低于对照组的(34.65±8.74)U/L、(43.12±6.37)U/L、(25.03±4.25)μmol/L,差异均有统计学意义(均P<0.01)。研究组WBC、RBC、PT、APTT水平低于对照组,Hb、Alb、TP、PTA水平高于对照组(P<0.05)。研究组IL-1、IL-6、IL-10、CRP、CD8^(+)T淋巴细胞水平低于对照组,CD4^(+)T淋巴细胞、CD4^(+)/CD8^(+)高于对照组(P<0.05)。研究组PLT水平为(114.32±11.86)×10^(9)/L高于对照组的(81.25±11.26)×10^(9)/L(P<0.05)。研究组治疗总有效率为93.33%,低于对照组的80.00%(χ^(2)=4.615,P=0.032)。研究组不良反应低于对照组(P<0.05)。研究组病死率为1.67%,低于对照组的11.67%(χ^(2)=4.821,P=0.028)。结论特比澳可改善肝病合并血小板减少症患者各项功能,增加血小板,降低病死率,有效且安全性较高。

Objective To analyze the application effect of Recombinant Human Thrombopoietin(Tpiao)in patients with liver disease complicated with thrombocytopenia.Methods A total of 120 patients with liver disease and thrombocytopenia admitted to our hospital from March 2020 to March 2021 were selected and divided into control group and study group,which were treated with dexamethasone and the study group was treated with Tpiao.The liver function index,coagulation function,blood routine,inflammation related index,immune related index and platelet count(PLT)levels were compared,and the effectiveness and safety were analyzed.Results The levels of alanine transaminase(ALT),aspartate transaminase(AST)and total bilirubin(TBIL)in the study group were respectively[(28.89±6.55)U/L],[(33.14±5.56)U/L],[(16.98±3.63)μmol/L]lower than those in the control group(P<0.05).The levels of WBC,red blood cell(RBC),prothrombin time(PT)and activated partial thromboplastin time(APTT)in the study group were higher than those in the control group,and the levels of hemoglobin(HGB),albumin(ALB),thromboplastin(TP)and plasma thromboplastin antecedent(PTA)were higher than those in the control group(P<0.05).The levels of IL-1,IL-6,IL-10,C-reactive protein(CRP),and CD8^(+)in the study group were lower than those in the control group,and the levels of CD4^(+),CD4^(+)/CD8^(+)were higher than those in the control group(P<0.05).The level of PLT in the study group was[(114.32±11.86)×10^(9)/L]higher than that in the control group(P<0.05).The total effective rate of the study group was 93.33%,which was lower than that of the control group,which was 80.00%(χ^(2)=4.615,P=0.032).The adverse reactions in the study group were lower than those in the control group(P<0.05).The mortality rate of the study group was 1.67%,lower than that of the control group(11.67%)(χ^(2)=4.821,P=0.028).Conclusion Tpiao can significantly improve the functional abnormalities of liver disease patients with thrombocytopenia,increase PLT content,reduce mortality,with high effectiveness and high safety,the incidence of adverse events is low,can be used for the treatment of this disease.